Evidence map›Paper›PMID 34783436›Full record

ArticleJournal of applied clinical medical physics2022

Half-beam volumetric-modulated arc therapy in adjuvant radiotherapy for gynecological cancers.

Pei-Chieh Yu, Ching-Jung Wu, Hsin-Hua Nien, Louis Tak Lui, Suzun Shaw, Yu-Lun Tsai

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Dosimetric benefits of half-field arc in prostate cancer treatment.Physical and engineering sciences in medicine · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pei-Chieh YuDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.
Ching-Jung WuDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.
Hsin-Hua NienDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.
Louis Tak LuiDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.
Suzun ShawOncology Treatment Center, Sijhih Cathay General Hospital, New Taipei City, Taiwan.
Yu-Lun TsaiDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.

Funding

Cathay General Hospital Institutional CGH-MR-B10914
6 · The paper itself

Abstract

purposeThe purpose of this study is to introduce half-beam volumetric-modulated arc therapy (HVMAT), an innovative treatment planning technique from our work, for reducing dose to the organs at risk (OAR) during adjuvant radiotherapy for gynecological cancers. METHODS AND MATERIALS: Seventy-two treatment plans of 36 patients with gynecological cancers receiving adjuvant radiotherapy were assessed. Among them, 36 plans were designed using HVMAT and paired with the other 36 traditional volumetric-modulated arc therapy (VMAT) plans for each patient. The main uniqueness of the HVMAT designs was that it consisted of two opposite-shielded half-beam fields rotated inversely in two coplanar arcs, collocating with the specially-devised avoidance structures to enhance the control of the OAR doses. The dose distributions in HVMAT and VMAT were evaluated and compared using the random effects model.

resultsThe ratios of OAR doses in HVMAT compared with VMAT showed a comprehensive OAR dose reduction when using HVMAT (V

conclusionsHVMAT is capable of generating deep double-concave dose distributions with the advantage of reducing dose to several OARs simultaneously. It is highly recommended for pelvic irradiation, especially for treating gynecological cancers in adjuvant radiotherapy.

Indexed as

NeoplasmsRadiotherapy, Intensity-ModulatedHumansOrgans at RiskRadiotherapy, AdjuvantRadiotherapy DosageRadiotherapy Planning, Computer-Assistedadjuvant radiotherapygynecological cancerhalf-beam volumetric-modulated arc therapy

Identifiers

PMID34783436
PMCPMC8803303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.